Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F16%3A50005416" target="_blank" >RIV/62690094:18450/16:50005416 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/16:10329615 RIV/00179906:_____/16:10329615 RIV/61989592:15110/16:33160474

Result on the web

<a href="https://www.degruyter.com/view/j/pteridines.ahead-of-print/pterid-2016-0005/pterid-2016-0005.xml" target="_blank" >https://www.degruyter.com/view/j/pteridines.ahead-of-print/pterid-2016-0005/pterid-2016-0005.xml</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/pterid-2016-0005" target="_blank" >10.1515/pterid-2016-0005</a>

Result language

angličtina

Original language name

Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer

Original language description

Breast cancer is the most common malignant tumor in women in the Western world. Despite the advances in early diagnosis and multidisciplinary treatment, breast cancer remains on of the leading causes of cancer deaths in women. It is now widely accepted that even in patients with apparently localized tumors breast cancer represents a systemic disease. In fact, improved prognosis of patients with breast cancer during the last decades has been caused not only by timely diagnosis, but also by improved systemic therapy. Systemic therapy, including the administration of cytotoxic, hormonal or targeted drugs currently represents an essential integral part of the multidisciplinary management of cancer patients. In patients with breast cancer systemic therapy is commonly administered after surgery in the adjuvant setting. In patients with locally advanced breast cancer, the primary tumor is considered unsuitable for upfront surgery, and systemic treatment is administered as first therapeutic modality, followed by surgery. Based on the observation that this therapeutic approach converts inoperable tumors to tumors that can be surgically treated, primary systemic treatment is also being increasingly used in patients with operable tumors with the aim to allow less extensive surgery. Primary (neoadjuvant) chemotherapy also represents a model system to directly examine the effect of systemic therapy on the tumor and the host-tumor interactions.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FN - Epidemiology, infection diseases and clinical immunology

OECD FORD branch

—

Project

<a href="/en/project/NT13564" target="_blank" >NT13564: Predictive factors of pathologic response to neoadjuvant chemotherapy in patients with HER-2 positive or triple negative breast carcinoma</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pteridines

ISSN

0933-4807

e-ISSN

—

Volume of the periodical

27

Issue of the periodical within the volume

3-4

Country of publishing house

DE - GERMANY

Number of pages

9

Pages from-to

67-75

UT code for WoS article

000390413200003

EID of the result in the Scopus database

—